The prognosis of patients treated with everolimus for advanced ER‐positive, HER2‐negative breast cancer is driven by molecular features
暂无分享,去创建一个
A. Vincent-Salomon | P. Cottu | A. Schnitzler | M. Debled | G. Bataillon | Lounes Djerroudi | Gabrielle Deniziaut | L. Haik | Ivan Bièche | Hélène Salaün | Anne Schnitzler | I. Bieche